News
Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback